Loading clinical trials...

RS-tDCS for Cannabis Use Disorder: The C.A.R.E.S. Initiative | Clinical Trials | Clareo Health

RECRUITINGNA

RS-tDCS for Cannabis Use Disorder: The C.A.R.E.S. Initiative

Telehealth-Delivered tDCS for Cannabis Addiction Recovery: The C.A.R.E.S. (Cannabis Addiction Recovery Enhancement Stimulation) Initiative

NCT07184983•NYU Langone Health

View on ClinicalTrials.gov

Summary

The purpose of this sham-controlled pilot randomized controlled trial (RCT) is to evaluate the feasibility, safety, and preliminary efficacy of a one-month intervention consisting of 20 home-based active or sham RS-tDCS sessions paired with audio track guided mindfulness meditation practice in otherwise healthy adults seeking to reduce cannabis use in the context of cannabis use disorder (CUD).

Eligibility

Age

22 - 65 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. Aged 22-65 years (inclusive)
•2. Currently meets the Diagnostic and Statistical Manual of Mental Disorders (DSM-V) criteria for CUD, as determined by DSM-V criteria (M.I.N.I)
•3. Positive for cannabis on the 11-COOH-THC single panel urine test
•4. Seeking treatment to reduce or discontinue cannabis use (Marijuana Ladder ranged between 5-8 \[inclusive\])
•5. Kessler Psychological Distress Scale (K10) score \< 35 (minimal to moderate distress)
•6. Wide Range Achievement Test-5(WRAT-5) score ≥ 85
•7. Ability to use mobile devices
•8. Fluent in English or Spanish

Exclusion Criteria

•1. Cannabis is used exclusively as prescribed or directed by their provider
•2. Meets DSM-V criteria for substance use disorder within the past six months for any psychoactive substance other than cannabis
•3. Meets DSM-V criteria for alcohol use disorder within the past six months
•4. Primary psychiatric disorder (major depressive disorder, bipolar disorder, or psychotic disorder) as the principal diagnosis, independent of cannabis use disorder; or current diagnosis of bipolar disorder, psychotic disorder, or any other alcohol/substance use disorder as defined by DSM-5-TR and confirmed via the Mini-International Neuropsychiatric Interview (MINI).
•5. Primary neurologic or major medical disorder that would interfere with study participation.
•6. Enrolled in group or individual therapy for substance use disorder that would be concurrent with the study intervention
•7. History of moderate or severe traumatic brain injury
•8. Seizure disorder or recent (\<5 years) seizure history
•9. Presence of metal or active implants in the head/neck
•10. Any skin disorder or skin sensitive area near stimulation locations
+1 more criteria

Locations (1)

NYU Langone Health

New York, New York, United States

Key Dates

Start Date

November 12, 2025

Primary Completion Date

October 1, 2026

Completion Date

November 1, 2027

Last Updated

November 13, 2025

Enrollment

ESTIMATED participants

Conditions

Cannabis Use Disorder

Interventions

Active Transcranial Direct Current Stimulation (tDCS)

DEVICE

Sham Transcranial Direct Current Stimulation (tDCS)

DEVICE

Mindfulness meditation

BEHAVIORAL

Contacts

Shayna Pehel

CONTACT

929-455-5104 Shayna.Pehel@nyulangone.org

Giuseppina Pilloni

CONTACT

929-455-5317 Giuseppina.Pilloni@nyulangone.org

Phenotyping Patients With Alcohol and Cannabis Use Disorders Using the Addictions Neuroclinical Assessment

NCT05855668

Alcohol Use DisorderCannabis Use Disorder

View study

RECRUITINGNA

Preliminary Efficacy Trial of a Digital Intervention for Depression and Cannabis Use

NCT06878859

Depression - Major Depressive DisorderCannabis Use Disorder+1 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: November 13, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

RS-tDCS for Cannabis Use Disorder: The C.A.R.E.S. Initiative

Inclusion Criteria

Exclusion Criteria

Phenotyping Patients With Alcohol and Cannabis Use Disorders Using the Addictions Neuroclinical Assessment

Preliminary Efficacy Trial of a Digital Intervention for Depression and Cannabis Use

Cannabinoids and Biological Reactivity to Stress

Genetics of Cannabis Use Disorder and Cannabinoid Response in Humans

Deep Repetitive Transcranial Magnetic Stimulation for Cannabis Use Disorder

Testing the Efficacy of the Cannabis Clinic for Patients With Psychosis (CCP) Intervention for Cannabis Use Reduction/Cessation in Patients With First Episode Psychosis (FEP)